Janus Henderson Group Ltd. filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 2,471,354 common shares of Blossomhill Therapeutics, Inc., representing 7.8% of the class, as of a triggering event dated September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: Janus Henderson Group Ltd. reported beneficial ownership of 2,471,354 common shares of Blossomhill Therapeutics, Inc.
- Percent of class: The 2,471,354 shares represent 7.8% of the outstanding class of common shares, according to the filing.
- Shared voting and dispositive power: All 2,471,354 shares are held with shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
- No individual Managed Portfolio exceeds 5%: The filing states that none of the underlying Managed Portfolios individually owns more than five percent of Blossomhill Therapeutics' common shares.
- Triggering event date: The date of the event requiring this filing is stated as September 30, 2026.
- Filer classification: Janus Henderson Group Ltd. is identified as a parent holding company (type HC), organized in Jersey, with its principal business office in London, United Kingdom.
Janus Henderson's Disclosed Position in Blossomhill Therapeutics as of September 30, 2026
According to the Schedule 13G filing, Janus Henderson Group Ltd. (JHG) is the ultimate parent of a number of SEC-registered investment advisers and foreign equivalents, including Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Victory Park Capital Advisors LLC, and Richard Bernstein Advisors LLC, among others. The filing refers to these entities collectively as the "Asset Managers." The Asset Managers generally exercise investment and voting discretion on behalf of client portfolios described in the filing as "Managed Portfolios," which include investment companies, institutional separate accounts, and retail separate accounts.
The filing states that as a result of this exercise of investment and voting discretion, the Asset Managers "may be deemed to be the beneficial owner of 2,471,354 common shares of Blossomhill Therapeutics, Inc." However, the filing also notes that "the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights." The right to receive dividends and sale proceeds is attributed to the Managed Portfolios themselves.
The filing was signed by Kristin Mariani, identified as Head of North America Compliance at Janus Henderson Group Ltd., and dated November 16, 2026. The issuer, Blossomhill Therapeutics, Inc., is listed with a principal executive office address of 10255 Science Center Drive, Suite 200, San Diego, CA 92121. The common shares carry CUSIP number 095130100. The filing does not reference a ticker symbol on the cover page's registered-securities table.
What Was Disclosed
Janus Henderson Group Ltd. disclosed, via Schedule 13G filed November 16, 2026, that it beneficially owns 2,471,354 common shares of Blossomhill Therapeutics, Inc., equal to 7.8% of the class, all held with shared rather than sole voting and dispositive power, as of September 30, 2026.



Please wait processing your request...